Boehringer Ingelheim is planning to expand its collaboration with Vanderbilt University in the development of anti-cancer drugs.

The partnership, announced March 13, will seek to develop new “chemical therapeutics” targeting a protein called MCL1 as a potential therapy against some cancers.

This is the third collaboration between Boehringer Ingelheim, a German-owned pharmaceutical company with a research complex in Ridgebury that is Ridgefield’s largest taxpayer, and Vanderbilt University in Nashville, Tenn.

“Boehringer Ingelheim and Vanderbilt University have the expertise and are jointly focused on discovering breakthrough medicines against the cancer causing proteins,” Darryl McConnell Ph.D., vice president and research site head for Boehringer Ingelheim, Austria, said